Results 41 to 50 of about 589 (105)

Real‐World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis

European Journal of Haematology, Volume 117, Issue 1, Page 174-185, July 2026.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real‐world evidence. Methods A systematic search was conducted following the PRISMA 2020 guidelines.
M. L. Lozano, D. Valcarcel
wiley   +1 more source

Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single‐center observational study in China

Pediatric Investigation
Importance Eltrombopag has been recommended for pediatric immune thrombocytopenia (ITP). Response and adverse drug reactions (ADRs) varied widely between individuals, even at the same dose of eltrombopag.
Shuyue Dong, Zhifa Wang, Nan Wang, Jingyao Ma, Jinxi Meng, Yixin Sun, Xiaoling Cheng, Runhui Wu   +7 more
doaj   +1 more source

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

British Journal of Haematology, EarlyView.
Jong Wook Lee, Kohei Hosokawa, Jun Ho Jang, Naoshi Obara, Masashi Sawa, Kensuke Usuki, Gaku Oshikawa, Masahiro Kizaki, Koji Nagafuji, Ting‐An Lin, Hitoshi Hanamoto, Yeung‐Chul Mun, Toshiro Kawakita, Kazunori Imada, June‐Won Cheong, Sung‐Soo Park, Takayuki Tabayashi, Masaru Gamou, Kenta Murotani, Hirohito Yamazaki   +19 more
wiley   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL.
Barbara Eichhorst, Paolo Ghia, Francesc Bosch, Ruth Clifford, Michael Gregor, Romain Guieze, Arnon P. Kater, Carsten U. Niemann, Sarka Pospisilova, Tadeusz Robak, Anna Schuh, Kostas Stamatopoulos, Tamar Tadmor, Nick York   +13 more
wiley   +1 more source

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques

Blood Vessels, Thrombosis & Hemostasis
: Thrombopoietin receptor agonists, for example eltrombopag, are standard second-line treatment for immune thrombocytopenia (ITP). Eltrombopag has demonstrated high response rates, both in clinical trials and in routine practice studies.
Tomás José González-López, Ricardo Sanchez, Carmen Pastoriza, Pavel Olivera, Silvia Bernat, Fernando Fernandez-Fuertes, Isabel Socorro Caparrós-Miranda, Gloria Pérez-Rus, Isidro Jarque, Maria Esperanza Moreno-Beltrán, Emma López-Abadía, Erik De Cabo, Shally Marcellini, Gloria Pérez-Segura, Carmen Fernández-Miñano, María Jesús Peñarrubia, Sergio Matarraz, María Pérez-Caro, Alberto Orfao, Drew Provan, Joaquín Martínez-López   +20 more
doaj   +1 more source

A case of immune thrombocytopenia due to miliary tuberculosis effectively treated with eltrombopag

Respiratory Medicine Case Reports, 2020
An 80-year-old woman was diagnosed with miliary tuberculosis. Laboratory findings showed marked thrombocytopenia (3000/μl). Immune thrombocytopenia (ITP) was diagnosed because platelet transfusion was ineffective, and bone marrow puncture demonstrated a ...
Hiroshi Wada, Takuto Sakashita
doaj   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience

Leukemia Research Reports, 2019
Background: Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown. Methods: We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018 ...
Akiko Konishi, Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Ryo Saito, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura   +12 more
doaj   +1 more source

Pragmatic Clinical Trial of Fostamatinib as Second‐Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial

eJHaem, Volume 7, Issue 4, August 2026.
Amber Afzal, Robert Kribs, Sumit Sawhney, Mohit Narang, Frances Blevins, Robert Numerof, Francois Di Trapani, Sherry Ladha, Ruchika Goel   +8 more
wiley   +1 more source

Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five‐Year Single‐Center Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Objectives Immune thrombocytopenia (ITP) during pregnancy presents unique management challenges. This study represents the first analysis of ITP outcomes during pregnancy in Qatar, aiming to assess maternal and neonatal outcomes at a tertiary care center.
Sarah A. Elkourashy, Hassan Magboul, Abdulrahman F. Al‐Mashdali, Mohammed Alnajjar, Naela AlMallahi, Elmustafa Abdalla, Dina Sameh Soliman, Sara Aldali, Manar E. Abdel‐Rahman Elhassan, Honar Cherif, Shehab F. Mohamed   +10 more
wiley   +1 more source